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ablation.Endoscopic treatment is recommended for patients with Barrett’s esophagus (BE) with
high-grade dysplasia, yet clinical management recommendations are inconsistent for pa-
tients with BE without dysplasia (NDBE) or with low-grade dysplasia (LGD). We used a
comparative modeling analysis to identify optimal management strategies for these
patients.METHODS: We used 3 independent population-based models to simulate cohorts of 60-year-old in-
dividuals with BE in the United States. We followed up each cohort until death without
surveillance and treatment (natural disease progression), compared with 78 different stra-
tegies of management for patients with NDBE or LGD. We determined the optimal strategy
using cost-effectiveness analyses, at a willingness-to-pay threshold of $100,000 per quality-
adjusted life-year (QALY).RESULTS: In the 3 models, the average cumulative incidence of esophageal adenocarcinoma was 111
cases, with costs totaling $5.7 million per 1000 men with BE. Surveillance and treatment of
men with BE prevented 23% to 75% of cases of esophageal adenocarcinoma, but increased
costs to $6.2 to $17.3 million per 1000 men with BE. The optimal strategy was surveillance
every 3 years for men with NDBE and treatment of LGD after confirmation by repeat
endoscopy (incremental cost-effectiveness ratio, $53,044/QALY). The average results for
women were consistent with the results for men for LGD management, but the optimal
surveillance interval for women with NDBE was 5 years (incremental cost-effectiveness
ratio, $36,045/QALY).CONCLUSIONS: Based on analyses from 3 population-based models, the optimal management strategy for pa-
tient with BE and LGD is endoscopic eradication, but only after LGD is confirmed by a repeat
endoscopy. The optimal strategy for patients with NDBE is endoscopic surveillance, using a
3-year interval for men and a 5-year interval for women.Keywords: ICER; EET; Radiofrequency Ablation; RFA; EAC.er: BE, Barrett’s esophagus; EAC, esoph-
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What You Need to Know
Background
1962 Omidvari et al Clinical Gastroenterology and Hepatology Vol. 18, No. 9See editorial on page 1930.Management recommendations for patients with
Barrett’s esophagus without dysplasia or with low-
grade dysplasia (LGD) are inconsistent.
Findings
Based on analyses from 3 population-based models,
the optimal management strategy for patient with
Barrett’s esophagus and LGD is endoscopic eradica-
tion, but only after LGD is confirmed by a repeat
endoscopy. The optimal strategy for patients with
Barrett’s esophagus without dysplasia is endoscopic
surveillance, using a 3-year interval for men and a 5-
year interval for women.
Implications for patient care
These findings have implications for management of
patients with Barrett’s esophagus and can inform
policy development and practice decisions.Esophageal adenocarcinoma (EAC) is the mostcommon subtype of esophageal cancer in the
United States and other Western countries.1 The inci-
dence and mortality of EAC have increased dramatically
since the 1970s.2 Barrett’s esophagus (BE) is the only
known precursor lesion for EAC.3 Therefore, clinical
guidelines recommend endoscopic surveillance and/or
treatment of BE patients depending on the presence and
grade of dysplasia. There is general consensus among
gastrointestinal professional societies regarding man-
agement of BE patients with high-grade dysplasia (HGD):
endoscopic eradication therapy (EET) using endoscopic
mucosal resection or endoscopic submucosal dissection
to remove endoscopically visible lesions, followed by
radiofrequency ablation (RFA) of flat dysplastic andmeta-
plastic epithelium should be performed. However, there is
uncertainty about the optimal surveillance interval for
nondysplastic BE patients (NDBE) and whether EET or
surveillance is the optimal management strategy for pa-
tientswith low-grade dysplasia (LGD) (Appendix Table 1).
Because of interobserver variation in the diagnosis of
dysplasia, particularly LGD, most clinical guidelines
recommend that a histologic diagnosis of LGD should be
confirmed by a second pathologist with expertise in
gastroenterological pathology. The American College of
Gastroenterology guidelines recommend endoscopic
eradication therapy for patients with confirmed LGD,
although endoscopic surveillance every 12 months is an
acceptable alternative.4 Of note, the American Gastroen-
terological Association recommends a repeat endoscopy
after proton pump inhibitor therapy for 8 to 12 weeks to
reduce inflammatory and regenerative changes that could
be misdiagnosed as dysplasia, before initiating EET.5
Optimal BE management should be guided by the
relative benefits and harms of competing strategies.
Because clinical trials are of insufficient duration to
assess cancer mortality and survival accurately, simula-
tion modeling studies are helpful to compare overall
effectiveness and cost effectiveness of different BE
management strategies throughout the lifetime of indi-
vidual patients and across populations. Population
models use aggregates of hypothetical individual event
histories associated with key components of a disease
process, based on available relevant data, to estimate
population-level effects of interventions on outcomes
and the comparative effectiveness of a variety of in-
terventions.6 A number of previous modeling studies,
including those conducted by our group, reported
inconsistent results on the management of LGD and
NDBE patients.7–11 Although these studies examined the
influence of variations in model parameters on conclu-
sions, the influence of variations in model structural as-
sumptions (eg, regression of dysplasia or metaplasia) on
conclusions could not be examined because most studies
were based on individual models. Moreover, priorstudies were not calibrated adequately to current
population-based EAC incidence and mortality. Finally,
the impact of repeat endoscopy to confirm LGD after
high-dose acid suppression to reduce false-positive test
results was not assessed.7–9
In this study we conducted a comparative effective-
ness analysis using 3 independently developed models to
determine the most cost-effective management strategy
for BE patients with LGD and the optimal interval for
surveillance of patients with NDBE.
Methods
We used 3 independent population-based models
that are part of the National Cancer Institute Cancer
Intervention and Surveillance Modeling Network to
compare the benefits, harms, and costs of different
management strategies for BE patients.
Cancer Intervention and Surveillance Modeling
Network Esophageal Adenocarcinoma Models
Three models were used for this analysis, as follows:
(1) Microsimulation Screening Analysis (MISCAN)-EAC
model from Erasmus University Medical Center (Rotter-
dam, The Netherlands) and the University of Washington
(Seattle, WA); (2) Esophageal Adeno Carcinoma Model
(EACMo), originally developed at the Massachusetts
General Hospital (Boston, MA) and currently at the
Columbia University Medical Center (New York, NY); and
(3) Multistage Clonal Expansion for EAC (MSCE-EAC)
model from the Fred Hutchinson Cancer Research Center
(Seattle, WA) (see the Appendix for details). Full de-
scriptions of the models are published and available
online.12
Figure 1. Differences in simulated strategies. The 78 simulated strategies were combinations of different options presented in
each column of this figure. LGD, low-grade dysplasia; NDBE, nondysplastic Barrett’s esophagus.
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For the main analysis, a hypothetical cohort of US
white men diagnosed with BE at age 60 in 2010 was
simulated and followed up until death or age 100,
whichever occurred first, without surveillance and BE
treatment (natural history). We separately simulated a
cohort of US white women diagnosed with BE at age 60
who underwent the same strategies.
Strategies Assessed
We compared 78 different BE management strate-
gies: the large number results from permutations in
surveillance intervals and differences in management of
LGD. In all strategies, HGD patients received EET con-
sisting of endoscopic mucosal resection of visible lesions
followed by RFA. The strategies varied in LGD manage-
ment, as follows: surveillance with different intervals, or
EET, with or without confirmation of LGD by a repeat
endoscopy after 2 months of high-dose acid suppression;
and in NDBE management, as follows: no surveillance or
surveillance with different intervals (1, 2, 3, 4, 5, and 10
y) (see Figure 1 and Appendix Table 2 for details).
Surveillance and Treatment Assumptions
Assumptions about the performance of surveillance
endoscopy were based on the current literature. We
assumed that individuals without BE could be mis-
diagnosed as NDBE with a probability of 0.075 (false-
positive rate) whereas NDBE patients were missed with
a probability of 0.125 (false-negative rate).13 Other pa-
tients were detected but could be misdiagnosed as NDBE,
LGD, HGD, or EAC with the probabilities specified in
Appendix Table 3. Misdiagnosis can be the result of
sampling error, misclassification, or disease regression.
Only 1 model (MSCE-EAC model) explicitly simulated all
3 pathways. Two models (MISCAN-EAC and EACMo)
captured all misdiagnoses in misclassification and sam-
pling errors, but did not distinguish these pathwaysseparately. In the MISCAN-EAC model, additional misdi-
agnosis may have occurred because of disease regres-
sion. However, the contribution to total misdiagnosis was
negligible.
All BE patients who received EET entered post-
treatment surveillance depending on the initial
dysplasia status of the patient and the outcome of the
EET (Appendix Table 4).5,14 Assumptions concerning the
efficacy of endoscopic therapy are presented in Appendix
Table 5 based on the pretreatment dysplasia status of the
BE patients.15 For recurrence of dysplasia or metaplasia
after initial EET, patients received RFA touch-ups fol-
lowed by surveillance (Appendix Table 4). Patients could
undergo a maximum of 3 RFA touch-ups, after which
management was limited to surveillance for early diag-
nosis of cancer.7 The stop age of surveillance and treat-
ments was assumed to be 80 years.
The duration of initial EET was assumed to be 2 years
in all strategies.7 Fifty-five percent of patients underwent
endoscopic mucosal resection of mucosal irregularities
(nodules, masses, or ulcers) before RFA.16 On average,
patients received 3.55 sessions of RFA during the initial
EET period.7 Complication rates of EET and endoscopies
were estimated based on the literature (see common
model inputs in Appendix Table 5).
Cost and Utility
The costs of surveillance endoscopy and EETs were
based on Centers for Medicare and Medicaid Services
reimbursement rates.17 Costs and utilities of cancer care,
perforation resulting from endoscopy, and complications
resulting from stricture were estimated based on the
published literature (Appendix Table 5). All costs were
adjusted for year 2015 using the US consumer price
index.18
Outcomes
For each strategy, we computed health outcomes
including the incidence of symptomatic and surveillance-
Table 1. Results of Base-Case Natural History and Selected BE Management Strategies (Average of the Models) per 1000 BE
Male Patients
Strategy and
outcome Natural history ND 5 y LGD 1 ya ND 3 y LGD 1 ya ND 3 y LGD 1 yb ND 3 y LGD EETb ND 3 y LGD EETa
EAC incidence 111 59 52 51 32 38
EAC mortality 77 26 21 21 12 15
Endoscopies – 7408 9882 10,234 9968 9158
Initial EET – 187 216 220 635 358
RFA touch-ups – 84 100 104 337 178
Cost, $1000
Cancer care 5668 3709 3302 3240 2162 2477
Endoscopies – 4149 5593 5830 5864 5327
EET/touch-
ups
– 994 1146 1178 3635 1994
Total cost 5668 8851 10,041 10,247 11,662 9799
LY 14,566 14,854 14,878 14,881 14,923 14,909
QALY 14,523 14,825 14,850 14,853 14,888 14,881
BE, Barrett’s esophagus; EAC, esophageal adenocarcinoma; EET, endoscopic eradication therapy; LGD, low-grade dysplasia; LY, life-years; ND, nondysplastic
Barrett’s esophagus; QALY, quality-adjusted life-year; RFA, radiofrequency ablation.
aLGD is not confirmed by a repeat endoscopy at 2 months.
bLGD is confirmed by a repeat endoscopy at 2 months.
1964 Omidvari et al Clinical Gastroenterology and Hepatology Vol. 18, No. 9detected EAC, EAC mortality, complications of endos-
copies and treatments, and life-years and quality-
adjusted life-years (QALYs) per 1000 BE patients. In
addition, we calculated the number of endoscopies, EETs,
RFA touch-ups, complications, and cancer care years to
estimate the total costs of surveillance and treatment per
strategy. The outcomes were analyzed for each model
separately, then the average results of the 3 models were
presented per strategy as the base case.19 Individual
model results were presented in the sensitivity analysis.
Analysis
The optimal strategy was identified through an in-
cremental cost-effectiveness analysis from a third-party
payer perspective using the average results of the 3
models.19 Costs and QALYs were discounted at an annual
rate of 3%. We performed an incremental cost-effective
analysis using a willingness-to-pay threshold (WTP) of
$100,000/QALY to determine the optimal BE manage-
ment strategy, which has been suggested to be consistent
with societal willingness to pay for medical
interventions.20
Sensitivity Analyses
We performed 7 sensitivity analyses to assess the
robustness of our results to our structural and param-
eter assumptions. First, we considered the results of each
model separately. In addition, we conducted a sensitivity
analysis using a more intensive post-treatment surveil-
lance of LGD patients consistent with the American Col-
lege of Gastroenterology recommendations,4 with
endoscopic surveillance every 6 months in the first year
after EET and then annually in the strategies in which
LGD patients underwent EET. We also conducted 1-waysensitivity analyses applying higher and lower values
than the main analysis for EET efficacy and recurrence
rates after complete eradication of intestinal metaplasia
after EET (Appendix Table 6). Finally, we performed a
probabilistic sensitivity analysis in which cost and utility
values, as well as the rate of complications of endoscopy
and EET, were varied simultaneously (Appendix
Table 7). In the probabilistic sensitivity analysis, we
also considered lower ($50,000) and higher ($150,000)
thresholds for cost effectiveness.Results
Results for Men
Without surveillance or EET, the models predicted an
average EAC cumulative incidence and mortality of 111
cases and 77 deaths per 1000 BE patients, respectively,
with a total cost of $5.7 million for the care of incident
EAC cases (Table 1). Surveillance or EET prevented 23%
to 75% of EAC cases and decreased mortality by 31% to
88% while increasing costs to $6.2 to $17.3 million,
depending on the management strategy (Appendix
Table 8).
The average results of selected different BE man-
agement strategies are presented in Table 1 to compare
the effect of different BE management strategies. Sur-
veillance with a 5-year interval for NDBE and a 1-year
interval for LGD patients without a confirmation endos-
copy decreased EAC incidence to 59 cases (-47%) and
EAC mortality to 26 (-66%) per 1000 BE patients. The
total costs increased to $8.9 million while gaining 302
more QALYs compared with the natural history.
Reducing the surveillance interval for NDBE patients to 3
years prevented more EAC cases and achieved greater
QALYs, but the total costs increased (Table 1).
Table 2. The Results of a Cost-Effectiveness Analysis per
1000 BE Male and 1000 Female Patients
Strategy Cost, $1000 QALY ICER, $/QALYa
Per 1000 BE male patients
Natural history 5668 14,523 –
ND 0 LGD EETb 6176 14,728 2476
ND 5 y LGD EETb 8672 14,855 19,779
ND 4 y LGD EETb 9148 14,869 32,850
ND 3 y LGD EETb,d 9799 14,881 53,044
ND 2 y LGD EETb 11,518 14,892 156,313
ND 2 y LGD EETc 13,253 14,894 1,105,045
ND 1 y LGD EETb 15,698 14,896 1,446,520
Per 1000 BE female patients
Natural history 3534 16,268
ND 0 LGD 1 y  2, 3 yc 4450 16,405 6716
ND 0 LGD EETb 4553 16,419 7561
ND 5 y LGD EETb,e 7448 16,499 36,045
ND 4 y LGD EETb 8064 16,504 118,233
ND 3 y LGD EETb 8839 16,508 202,874
ND 3 y LGD EETc 10,869 16,511 700,093
BE, Barrett’s esophagus; EET, endoscopic eradication therapy; ICER, incre-
mental cost-effectiveness ratio; LGD, low-grade dysplasia; ND, nondysplastic
Barrett’s esophagus; QALY, quality-adjusted life-year; 1 y  2, 3 y, surveillance
every 1 year for 2 years, thereafter every 3 years.
aThe ICERs were calculated before rounding the numbers reported for costs
and QALYs in this table.
bLGD is confirmed by a repeat endoscopy at 2 months.
cLGD is not confirmed by a repeat endoscopy at 2 months.
dThe optimal strategy was EET after confirmation by repeat endoscopy for LGD
patients and surveillance every 3 years for NDBE patients. Strategies that were
dominated are not shown in the table.
eThe optimal strategy was EET after confirmation by repeat endoscopy for LGD
patients and surveillance every 5 years for NDBE patients. Strategies that were
dominated are not shown in the table.
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and decreased EAC incidence and mortality compared
with surveillance for LGD. The strategy with EET for LGD
patients after endoscopic confirmation with surveillance
every 3 years for NDBE patients decreased EAC inci-
dence and mortality to 38 cases (-66%) and 15 deaths
(-81%) per 1000 BE patients compared with natural
history, respectively. The costs increased to $9.8 million
while gaining 358 more QALYs than natural history. EET
for LGD without endoscopic confirmation resulted in
slightly higher QALYs compared with EET for LGD with
confirmation, but the costs increased by almost $2
million per 1000 BE patients (Table 1).Cost-Effectiveness Analysis
Strategies using EET for LGD patients (either with or
without confirmation endoscopy) were generally more
effective than strategies with surveillance for LGD pa-
tients (Appendix Table 8). In men, only strategies
limiting EET to patients confirmed to have LGD on
endoscopic confirmation after acid suppression were
cost effective (Table 2, Figure 2A). Considering a WTP
threshold of $100,000, the optimal BE management
strategy for men was EET for endoscopically confirmedLGD after 2 months of acid suppression, and surveillance
every 3 years for NDBE patients (incremental cost-
effectiveness ratio, $53,044/QALY).
Results for Women
Predicted EAC cases in women were lower than in
men (75 and 111 per 1000 in women and men, respec-
tively). Consequently, QALYs gained from BE surveillance
and treatment were lower in women than in men, and
incremental costs per QALY gained for similar BE man-
agement strategies were higher. Most cost-effective
strategies in women included EET for LGD confirmed
by endoscopy after 2 months of acid suppression, similar
to results for men (Table 2, Figure 2B). Because of the
higher incremental costs per QALY gained in women, the
optimal strategy was surveillance every 5 years for
NDBE (incremental cost-effectiveness ratio, $36,045/
QALY).
Sensitivity Analysis
All 3 models consistently found EET to be the optimal
strategy for male BE patients with LGD (Table 3). How-
ever, because costs per QALY gained were generally
lower in the MISCAN-EAC model, the optimal strategy for
male NDBE patients varied from surveillance every
2 years (MISCAN-EAC) to surveillance every 3 years
(EACMO and MSCE-EAC) (Appendix Tables 9–14).
The optimal strategy for men did not change in the
1-way sensitivity analyses: applying a more intensive
surveillance strategy after treatment of LGD patients, a
higher or lower value for EET efficacy, or a higher or
lower value for recurrence rate after complete eradiation
of metaplasia after receiving EET (Table 3, Appendix
Tables 15–19). Results also were robust to wide varia-
tions in assumptions on complication rates, cost, and
utility values. The optimal BE management strategy for
men (EET after confirmation by repeat endoscopy after
acid suppression for LGD patients and surveillance every
3 years for NDBE patients) was optimal in 100% of runs
in probabilistic sensitivity analyses for WTP thresholds
of $67,500 to $137,500/QALY (Figure 3).
Discussion
Our comparative modeling analysis indicated that the
most cost-effective strategy for patients with BE and LGD
is EET, but only if the LGD is confirmed by a repeat
endoscopy after 2 months of high-dose, acid-suppression
therapy. Our analysis also found that the most cost-
effective strategy for NDBE patients is surveillance
every 3 years in men but every 5 years in women.
We found that none of the strategies using surveil-
lance for LGD patients, or EET without confirmation of
LGD, were cost effective in men. For women, only 1 of 7
efficient strategies used surveillance for LGD. This
Figure 2. Results of a cost-
effectiveness analysis for
(A) men and (B) women.
cConfirmed by a repeat
endoscopy at 2 months.
*The optimal strategy for
men was EET after confir-
mation by repeat endos-
copy for LGD patients and
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and the wide variation in assumptions examined in the
sensitivity analyses. Despite the potential harms and cost
of endoscopic therapy, EET of LGD reduces the numberof endoscopies required for surveillance of LGD patients
because of prolonged surveillance intervals after suc-
cessful treatment and generally prevents more EAC cases
than strategies using only surveillance for LGD.
Table 3.Optimal Management Strategy by Analysis for Male BE Patients
Analysis NDBEa LGD EAC preventedb Net cost ($1000)b QALY gainedb ICER, $/QALYc
Base-cased 3 y 2 mo,e EET 66% 4131 358 53,044
MISCAN-EAC model 2 y 2 mo,e EET 67% 6676 452 78,140
EACMo model 3 y 2 mo,e EET 67% 3514 365 67,225
MSCE-EAC model 3 y 2 mo,e EET 67% 3822 278 84,564
More intensive post-EET surveillanced 3 y 2 mo,e EET 66% 4785 353 68,199
Higher EET efficacyd 3 y 2 mo,e EET 70% 3785 364 49,379
Lower EET efficacyd 3 y 2 mo,e EET 62% 4458 341 59,180
Higher recurrence rate after CE-IMd 3 y 2 mo,e EET 59% 5007 338 66,501
Lower recurrence rate after CE-IMd 3 y 2 mo,e EET 66% 4131 358 49,115
BE, Barrett’s esophagus; CE-IM, complete eradication of intestinal metaplasia; EACMo, Esophageal Adeno Carcinoma Model; EET, endoscopic eradication
therapy; ICER, incremental cost-effectiveness ratio; LGD, low-grade dysplasia; MISCAN, Microsimulation Screening Analysis; MSCE, Multistage Clonal Expan-
sion; NDBE, nondysplastic Barrett’s esophagus; QALY, quality-adjusted life-year.
aThe numbers in the column show the optimal surveillance interval.
bPer 1000 BE patients compared with natural history.
cThe ICERs were calculated before rounding the numbers reported for costs and QALYs in this table.
dCombined results of the models (mean).
eConfirmatory endoscopy at 2 months, if LGD is confirmed then an EET.
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expensive than some surveillance-only strategies, while
gaining greater QALYs. Importantly, confirmation of LGD
before EET is more cost effective than EET without
confirmation. Confirmatory endoscopy decreases the
number of false-positive results of LGD diagnosis.
Although 1 more endoscopy is required per BE patient,
the additional costs are compensated by the reduced
number of inappropriate EETs (ablation of misdiagnosed
NDBE patients).
The 3 models are less consistent in identifying the
optimal strategy for NDBE patients, although 2 modelsFigure 3. Results of a probabilistic sensitivity analysis by willin
men. cConfirmed by a repeat endoscopy at 2 months. ncNot con
dysplasia; ND, nondysplastic Barrett’s esophagus.showed that surveillance every 3 years is the optimal
strategy for men, the MISCAN-EAC model suggested that
surveillance every 2 years is optimal. This discrepancy
can be explained by different model assumptions be-
tween the 3 models (eg, on regression and progression of
BE patients).
Prior analyses reported inconsistent findings
regarding the management of NDBE patients. A modeling
study in Australia reported that surveillance of all NDBE
patients likely was not cost effective,21 whereas studies
in The Netherlands and the United States reported that
surveillance of NDBE patients could be cost effectivegness-to-pay thresholds ($ per quality-adjusted life-year) for
firmed. EET, endoscopic eradication therapy; LGD, low-grade
1968 Omidvari et al Clinical Gastroenterology and Hepatology Vol. 18, No. 9using a 3- or 5-year interval, respectively.10,22 These
studies were limited by the use of a single model/natural
history,8,9 and they examined fewer competing manage-
ment strategies.
In our analysis, we simulated cohorts of 60-year-old
BE patients because the mean/median age of BE patients
at diagnosis is older than 60 years.23,24 In all strategies,
the stop age of surveillance was assumed to be 80 years.
This stopping age was chosen to reflect the balance be-
tween benefits and harms of surveillance with increasing
age. The US Preventive Services Task Force recom-
mended age 75 for the stopping age of average-risk in-
dividuals for colorectal cancer and breast cancer
screening.25,26 We chose the higher age of 80 because
patients with BE, even NDBE, are no longer average risk.
An innovative feature of our analysis was the ability
to test different structural assumptions about the natural
history of progression from BE to EAC by comparing
3 independently developed models. Two models (MIS-
CAN-EAC and MSCE-EAC) assumed that regression from
HGD to LGD and from LGD to NDBE can occur in the
absence of EET, while the third model (EACMo) did not
allow regression to occur. The MSCE-EAC model is based
on the molecular and cellular changes that underlie the
progression from normal squamous epithelium to BE
and to EAC, whereas the other 2 models are population-
based cohort simulations reflecting the clinically identi-
fiable stages leading to EAC development. All models are
calibrated independently to reproduce Surveillance,
Epidemiology, and End Results data and use identical
clinical parameter estimates (variable values)27; howev-
er, the manner in which these variables interact differs
substantially between models. Despite these differences
in model structure, our results were remarkably
consistent. A further strength of our study was the ability
to present a sensitivity analysis that simultaneously
varied the estimated values of variables in 3 models with
unique natural history assumptions about BE and EAC.
For these reasons, we believe our comparative modeling
results are more robust than prior studies in which an-
alyses were limited to a single model.
Our study had several limitations. A major concern
was the limited amount of published long-term EET
outcome data. For this reason, short-term clinical effects
were used to inform our models and extrapolated to
project long-term effects, and we conducted sensitivity
analyses applying higher and lower values for EET effi-
cacy and recurrence rates after complete eradication of
metaplasia. Furthermore, there was limited evidence
regarding the association of multifocal LGD or LGD with
nodularity and progression5; and only 1 of our models
(MSCE-EAC) explicitly modeled mutations throughout
the tissue that may lead to multifocal clonal growth. This
is an area with less information, requiring more explor-
ative research in the future. In addition, the underlying
prevalence of BE driving the overall incidence of EAC is
unknown and, for this reason, the models differed in the
numbers of total EACs (preclinical and clinicallydetected) estimated over the lifetime of the cohort. Cost
estimates used Centers for Medicare and Medicaid Ser-
vices data, which are relevant to individuals 65 years of
age and older and may have underestimated the costs
incurred in individuals 60 to 64 years of age in this
study. Finally, utilities were estimated from limited data
and may not represent individual preferences for
different health states accurately. Therefore, we con-
ducted a probabilistic sensitivity analysis on cost and
utility values to evaluate the impact of our assumptions
on our results.
Notwithstanding these limitations, our analysis has
important implications for the management of BE patients
and can inform BE policy development and practice de-
cisions. We focus particularly on BE patients without
dysplasia or with LGD, who represent the majority of
patients diagnosed with BE. The management of BE,
particularly LGD, has received inconsistent recommenda-
tions from societies. In addition to informing US guide-
lines, our findings are applicable in other settings. The
analyses in our study were conducted for a US cohort, but
we expect similar results for BE populations in other
settings with similar BE progression rates and high EAC
incidence such as Northern and Western Europe.28–32
In summary, our comparative modeling analysis us-
ing 3 independent simulation models found that the
most cost-effective management strategy for BE patients
with LGD is EET, if LGD is confirmed by a repeat
endoscopy after 2 months of high-dose, acid-suppression
therapy. For NDBE patients, our analysis found the
optimal cost-effective strategy is surveillance at 3-year
intervals for men and at 5-year intervals for women.
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